Shaping your portfolio
from the patent up

In most industries, asserted independent claims are shorter

Across every industry except pharma, biotech, healthcare, and education, asserted patents had shorter median independent claims than the control group: 150 words asserted vs 167 control overall, and only ~10% of asserted patents have independent claims over 300 words.

The outliers, where asserted claims skew longer: pharma (83 asserted vs 48 control), biotech (92 vs 82), healthcare (182 vs 169), and education (213 vs 124) — though the last two carry a small-sample caveat, with only 65 and 32 litigations respectively against an industry average of 550.

In many fields, shorter independent claims reflect cleaner, more targetable claim architecture. In some domains — especially life sciences — the "assertable" pattern can look different.

Claim length varies by who's asserting

Segmenting by plaintiff type moves the median meaningfully. NPEs and operating companies draft to a similar length (~150 words). Universities are notably shorter at 122 words — potentially more foundational, early platform claims. Individual inventors are the longest at 213 words: more narrative drafting, more limitations, less professional constraint.

Asserted patents are also "beefier" everywhere else

Even when independent claims are shorter, asserted patents skew toward more disclosure density: longer specifications (8,400 median words vs 7,100 control), more figures (13 vs 11), and bigger claim sets — 41% of asserted patents have more than 20 claims, vs 18% of controls.

Before you file, a quick check: if an independent claim runs 300+ words, there should be a very intentional reason. And if you want enforcement flexibility later, you often get more mileage from a richer spec — embodiments, broader definitions, more edge cases.

NPE vs OpCo assertions split evenly — but the mix diverges by industry

Some portfolio strategists assume most patent risk is "NPE risk"; others assume it's "OpCo risk." Both can be correct. The aggregate: ~3,300 NPE vs OpCo litigations, ~3,000 OpCo vs OpCo, and under 2% from individuals, universities, and governments combined. (The only government plaintiff in the dataset was Canada, asserting plant patents.)

Among industries with at least 50 litigations, NPE-dominated territories include healthcare services (5.5 NPE cases per OpCo case), transportation & logistics (5.5:1), retail & e-commerce (5.1:1), and telecommunications (3.1:1). OpCo-dominated territories: pharmaceuticals (86:1), biotechnology (14.8:1), chemicals & materials (7.3:1), energy & oil/gas (6.0:1), and clean tech (3.9:1).

Filing volume ≠ assertion volume

Some industries file heavily while assertions concentrate elsewhere. Non-asserted patents skew toward semiconductors & electronics (~21% of the control group). OpCo assertions skew toward consumer goods (15%), software (13%), pharma (10%), and biotech (9%); NPE assertions skew toward software (20%), semiconductors (17%), and consumer goods (14%). High filing density does not automatically translate into litigation or licensing leverage.

Industry shifts show where leverage is rising and fading

Litigation risk is dynamic. The fastest-growing assertion areas: NPE activity in healthcare (+13% CAGR) and financial services (+9%); OpCo activity in automotive (+25%) and financial services (+25%). The fastest-declining: NPE telecom (−24%) and semiconductors (−15%); OpCo pharma (−27%) and biotech (−16%). Portfolios built solely around historical hotspots can quietly drift out of alignment with where leverage is actually moving.

Bigger companies get sued more

Assertion frequency increases with defendant market cap. No surprise — but it matters less as a fun fact and more as a targeting reality: larger companies attract both OpCo enforcement and NPE monetization, so portfolios aimed at licensing or deterrence need to align with who actually has money on the table.

Asserted patents are more often acquired than organic

The baseline split: control patents are ~38% acquired and ~62% organic. Asserted patents flip it — ~55% acquired, ~45% organic. In other words, assertion is more often bought than built. That alone challenges a common assumption: that the patents most likely to matter are the ones you happened to invent internally.

This isn't just an NPE phenomenon

It's tempting to dismiss this as "NPE behavior," but the data doesn't support that. Operating companies also rely heavily on acquired patents for enforcement: of all patents asserted by OpCos, 42% are acquired rather than internally developed. Even companies with deep R&D pipelines regularly rely on the secondary market to fill enforcement-relevant gaps. Acquisition isn't a corner case — it's a structural feature of how asserted portfolios are built.

NPEs buy private-origin patents — but tap public companies more than OpCos do

NPE acquisitions skew heavily toward private-origin patents — inventors, startups, small holders. But patents originally filed by publicly traded companies make up 29% of NPE acquisitions vs 24% of OpCo acquisitions: NPEs are more active than OpCos at extracting value from public-company divestitures. That matters because public-origin patents often come with more mature prosecution histories, better documentation, and clearer technology-to-market alignment.

Public and private OpCos acquire very differently

Among operating companies, acquisition behavior splits sharply: public OpCos acquire from public and private sources at roughly equal rates, while private OpCos acquire predominantly private-origin portfolios.

Asserted patents come from larger families, across industries

Across most industries, asserted patents live in meaningfully larger families than non-asserted controls — median family size ~36% larger, based on ~550 litigations per industry. The exceptions are two small-sample industries (healthcare services at ~65 litigations, education at ~32) where asserted and control family sizes are nearly identical. Larger families don't guarantee assertion, but assertion rarely happens without meaningful family depth.

Pharma and biotech are extreme outliers

Life sciences don't just follow the trend — they amplify it. Median family size for asserted pharma patents is 50 vs 17 for controls; biotech runs 48 vs 15. That's a 200%+ difference. In these domains, leverage is cumulatively built through layered protection, jurisdictional coverage, and adjacent claim sets over time to create a patent thicket.

Continuations are dramatically more common in asserted patents

The continuation-rate data matches the family-size data: ~50% of asserted patents are continuations vs ~20% of controls. Asserted portfolios are not static snapshots — they're actively shaped over time.

At a portfolio level, OpCos lean slightly more toward asserting continuation-heavy assets (≈3,450 continuations vs ≈3,200 non-continuations), while NPE assertions skew slightly toward non-continuations (≈1,500 vs ≈1,900). OpCo assertion behavior appears more "prosecution-shaped" — built via continuation strategy — though continuations are a major component for both.

Very large families are rare but heavily skew toward assertion

Families of 20+ members hold 9% of asserted patents vs 1% of controls. This isn't about filing everywhere indiscriminately — it's about keeping optionality alive where it matters. Across industries, one pattern keeps repeating: shorter, cleaner claims; richer disclosures; continuation-heavy families. Litigation risk (and licensing leverage) skews toward patents that weren't treated as one-and-done filings, but as evolving assets. This also explains why acquisition is so common in asserted portfolios: buyers may value the family optionality, not just the individual patent.

Forward citations are one of the oldest rules of thumb in patent analytics: more citations = more value. The last five years of litigation data mostly agree — but the signal is weaker and noisier than expected. To avoid self-referential citation counts, this analysis covers 4,300 original utility patents (excluding continuations) against a randomly granted control group from the same priority window.

On average, asserted patents are cited far more often

At a high level, the classic story holds: average forward citations run 43 asserted vs 9 control; medians run 12 vs 2. If you had to pick a single metric blind, forward citations would still outperform most alternatives.

But many asserted patents have surprisingly low citation counts

The distribution is where it gets interesting: 44% of asserted patents have below-average citation counts (fewer than 9), and 11% have zero forward citations. Meanwhile the high end skews dramatically — 5% of asserted patents have 100+ citations, vs just 0.1% of the control group. Citations are a strong signal on average, but a poor filter in isolation: a large fraction of asserted patents would be screened out by a hard citation threshold.

Citation-heavy ≠ enforcement-ready

This helps explain why citation-based rankings often disappoint in practice. Highly cited patents often reflect crowded technical fields, heavy examiner search activity, and follow-on innovation — not necessarily clean infringement targets. Meanwhile, some asserted patents sit in narrow but commercially important niches, cover late-emerging implementations, or map cleanly to products despite limited academic or patent follow-on.

Using ~9,700 asserted patents from the last five years, this chapter looks at timing, prosecution choices, and how patents age into leverage.

Most asserted patents don't max out claim count

A common assumption is that "important" patents load up on claims. The data doesn't support that: 59% of asserted patents stay at 20 claims or fewer (vs 82% of controls). Assertion is rarely driven by sheer claim volume — coverage quality and flexibility matter more than raw count.

Assertion is a mid-life event, not an early one

Only ~8% of asserted patents are asserted within 4 years of priority; ~32% within 9 years. The median age at assertion is ~13 years since priority. Most patents that get asserted spend a decade or more quietly sitting in portfolios before they ever matter — which means early drafting and prosecution decisions need to age well.

"This one matters" behavior shows up early

Looking back at prosecution history, asserted patents show higher rates of discretionary effort: Track One prioritized examination on ~15% of asserted patents vs ~5% of controls, and notices of appeal on ~7% vs ~3%. These aren't random artifacts — applicants recognized certain applications as strategically important and acted on that instinct, even when the payoff wouldn't arrive for years. The data supports what many practitioners suspect: those "this one matters" instincts are often right.

Several factors don't matter much

There's no meaningful difference between asserted and control patents for inventor count, and the patent-type mix (~93% utility, ~6% design, ~1% reissue, ~0.3% plant) is unremarkable. Enforcement readiness isn't about team size or patent class — it's about how the asset is positioned to mature over time.

Across claims, families, acquisitions, industries, and lifecycle timing, one theme keeps showing up: assertion is not random. It follows repeatable patterns — and those patterns are visible years before litigation.

1. Asserted patents are structurally different

At the patent level, asserted assets share a recognizable profile: cleaner independent claims (shorter and more targetable in many industries), richer specifications (more embodiments, figures, and optionality), and thoughtful prosecution choices (Track One, appeals, intentional effort where it "matters"). None of these guarantees enforcement — but taken together, they dramatically raise the odds that a patent can support real leverage later.

2. Leverage compounds through families, not single filings

Asserted patents rarely stand alone. They come from larger families, they are disproportionately continuations, and in pharma and biotech, family depth is often a significant source of leverage. This also explains why so many asserted patents are acquired: buyers are not paying for isolated claims, but for claims whose shape has been optimized by long, family-driven refinement.

3. Acquisition isn't a corner case — it's structural

More than half of asserted patents were acquired, not organically built. This is true for NPEs and OpCos, across public and private companies, and it reflects a simple reality: organic filing rarely produces complete coverage on its own. Treating acquisition as optional means leaving gaps that others are actively searching for.

4. Where patents matter is shifting, quietly

Assertion clusters don't perfectly track filing volume or R&D spend. Financial services, healthcare, and automotive are rising in relative assertion activity; telecom and semiconductors are declining; larger companies attract more enforcement regardless of intent. Portfolios that aren't periodically re-aligned drift out of sync with where leverage actually shows up.

5. Simple proxies work — until they don't

Forward citations, claim counts, and family size all correlate with assertion on average. But many asserted patents have low citation counts, many high-citation patents are never asserted, and no single metric captures enforcement readiness. The signal lives in how these factors combine, not in any one of them.